UroGen Pharma Ltd. (NASDAQ:URGN) Receives $43.70 Average PT from Analysts

UroGen Pharma Ltd. (NASDAQ:URGN) has been given a consensus rating of “Buy” by the six brokerages that are presently covering the firm, MarketBeat.com reports. Five equities research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $43.70.

A number of research firms have recently weighed in on URGN. EF Hutton Acquisition Co. I upgraded shares of UroGen Pharma to a “strong-buy” rating in a research note on Monday, October 14th. Oppenheimer reiterated an “outperform” rating and issued a $40.00 price objective on shares of UroGen Pharma in a report on Wednesday, October 16th. D. Boral Capital reiterated a “buy” rating and issued a $25.00 price objective on shares of UroGen Pharma in a report on Thursday, January 23rd. Finally, HC Wainwright reiterated a “buy” rating and issued a $60.00 price objective on shares of UroGen Pharma in a report on Tuesday, October 15th.

Institutional Trading of UroGen Pharma

Several hedge funds have recently modified their holdings of the stock. Coastal Bridge Advisors LLC increased its stake in shares of UroGen Pharma by 4.1% in the 2nd quarter. Coastal Bridge Advisors LLC now owns 38,500 shares of the company’s stock valued at $646,000 after acquiring an additional 1,500 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its stake in shares of UroGen Pharma by 90.9% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,100 shares of the company’s stock valued at $103,000 after acquiring an additional 3,856 shares in the last quarter. BNP Paribas Financial Markets increased its stake in shares of UroGen Pharma by 221.8% in the 3rd quarter. BNP Paribas Financial Markets now owns 8,546 shares of the company’s stock valued at $109,000 after acquiring an additional 5,890 shares in the last quarter. Tidal Investments LLC increased its stake in shares of UroGen Pharma by 19.1% in the 3rd quarter. Tidal Investments LLC now owns 37,595 shares of the company’s stock valued at $477,000 after acquiring an additional 6,030 shares in the last quarter. Finally, SG Americas Securities LLC increased its stake in shares of UroGen Pharma by 44.1% in the 4th quarter. SG Americas Securities LLC now owns 20,269 shares of the company’s stock valued at $216,000 after acquiring an additional 6,207 shares in the last quarter. Institutional investors own 91.29% of the company’s stock.

UroGen Pharma Trading Up 2.5 %

Shares of UroGen Pharma stock opened at $11.01 on Friday. The company has a market capitalization of $258.23 million, a price-to-earnings ratio of -3.50 and a beta of 1.09. The company has a quick ratio of 8.77, a current ratio of 9.00 and a debt-to-equity ratio of 4.77. UroGen Pharma has a 12-month low of $9.78 and a 12-month high of $20.70. The firm’s 50-day moving average price is $11.18 and its two-hundred day moving average price is $12.81.

UroGen Pharma (NASDAQ:URGN) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.55) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.84) by $0.29. The firm had revenue of $25.20 million for the quarter, compared to analyst estimates of $24.22 million. During the same quarter in the previous year, the company earned ($0.68) earnings per share. On average, analysts forecast that UroGen Pharma will post -3.1 earnings per share for the current fiscal year.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.